📅 2 September 2026🏷 Other Neurotoxins

Jeuveau: What Its FDA Trials Found, and the Side Effect That Was Worse on Placebo

By Lucas, Founder & Lead Researcher

Reviewed for medical accuracy against our Medical Review Board · Last updated 2 September 2026

Jeuveau is the neurotoxin sold as the cosmetic-only one. Its maker, Evolus, has no medical product line, and the FDA has approved Jeuveau for exactly one thing. That much is widely reported.

What is not reported is what its trial data actually says. We read the label. The side effect every Jeuveau page leads with was more common in the placebo group, and the label contains no statement of how long the product lasts.

The two numbers to take away. Jeuveau worked in 68% and 70% of patients across its two trials against a 1% placebo rate, which is a very wide margin. And headache was 12% on Jeuveau against 13% on placebo, so the trial did not show Jeuveau causing it.

What Jeuveau actually is

Jeuveau is prabotulinumtoxinA-xvfs, made by Evolus. Like every botulinum toxin type A product it blocks the release of acetylcholine at the nerve terminal, by cleaving a protein called SNAP-25, which partially and temporarily denervates the muscle it is injected into.

The vial is unusually simple. Each one contains 100 Units of botulinum toxin type A neurotoxin complex, 0.5 mg of human serum albumin and 0.9 mg of sodium chloride, vacuum-dried, with no preservative. That is the whole formulation. The toxin itself is a 900 kDa complex, meaning the neurotoxin arrives with its accessory proteins attached rather than stripped away.

Unopened vials are stored refrigerated at 2 to 8 degrees Celsius, in the original carton to keep light off them. If a clinic is storing it anywhere else, that is a question worth asking.

68% and 70%, against a 1% placebo

The approval rests on two trials of identical design, EV-001 and EV-002, which together enrolled 654 people randomised 3 to 1: 492 to Jeuveau and 162 to placebo.

The endpoint is stricter than most, and this is the part worth understanding. A responder had to show a 2-grade improvement from baseline at maximum frown on the 4-point Glabellar Line Scale, and it had to be scored that way independently by both the investigator and the patient. Not one or the other. Both.

Trial	Jeuveau	Placebo
EV-001	68% (N=246)	1% (N=84)
EV-002	70% (N=246)	1% (N=78)

A 1% placebo rate is the number to notice. It means that when a strict, double-scored endpoint is used, almost nobody untreated gets recorded as improved. Compare that with the dermal filler trials we have read, where untreated control groups were scored as improved anywhere from 8.8% to 39.1% depending on the scale used. Same idea, wildly different rigour.

The practical consequence: a neurotoxin success rate and a filler success rate are not comparable, and neither are two filler success rates. On this page the 68% is doing real work, because the thing it is measured against barely moved.

The side effect that was worse on placebo

Search for Jeuveau side effects and you will be told headache affects 12% of patients. That is straight from the label and it is true. It is also close to meaningless on its own, because the label prints the placebo column right beside it.

Reaction	Jeuveau (N=492)	Placebo (N=162)
Headache	57 (12%)	21 (13%)
Eyelid ptosis	8 (2%)	0 (0%)
Upper respiratory tract infection	13 (3%)	1 (1%)
White blood cell count increase	6 (1%)	0 (0%)

Headache was slightly more common among the people who got no drug at all. So the trial provides no evidence that Jeuveau causes headaches. People do get headaches after injections, and the placebo arm shows how many of those would have happened anyway.

The reaction that is attributable is eyelid ptosis, a drooping upper lid, at 2% against 0% on placebo. That is the one to ask about, because it is the one the drug caused, it is the direct consequence of injecting near the brow, and it resolves on its own but can take weeks or months. We cover what to do about it on our page on droopy eyelid after Botox, which applies to any product in this class.

One comparison worth keeping in perspective: the Letybo label reports headache at 2%. That is not evidence Letybo is gentler. Different trials, different populations, different placebo baselines. Jeuveau's own placebo group is the only fair comparison for Jeuveau's own numbers.

What the label says about how long it lasts, which is nothing

Here is the omission that surprised us most. The Jeuveau label states no duration of effect. There is no "results last three to four months" sentence in it. The only efficacy timepoint the trials report is Day 30.

What the label does say is this: "Retreatment of JEUVEAU should be administered no more frequently than every three months." Read it carefully, because it is routinely misquoted. That is a minimum safe interval, a floor on how often you may be injected. It is not a claim about when the effect wears off. The label adds that consideration of the cumulative dose is necessary.

So every "Jeuveau lasts 3 to 4 months" figure you will read, including on clinic sites, is extrapolated from practice and from the other toxins, not quoted from this product's approval. It may well be right. It is simply not a labelled claim.

A related gap, and this one is class-wide rather than a Jeuveau failing: the label states that "no formal pharmacodynamic studies have been conducted with JEUVEAU". The Letybo label contains the identical sentence about Letybo. So for two of the six brands there is no pharmacodynamic study underpinning any onset or fade timeline at all.

Why Jeuveau units cannot be compared to Botox units

The label is blunt about this, and it matters commercially. Jeuveau's potency is measured by an animal-based assay specific to Evolus's own product, in which one Unit equals the calculated median lethal dose in mice for that assay.

Because the assay is product-specific, the label states that units of Jeuveau cannot be converted into units of any other botulinum toxin assessed by any other method. Every product in this class carries the same statement about itself.

This is the mechanism behind most misleading price comparisons. A clinic quoting a lower per-unit price for one brand is not necessarily cheaper, because a unit is not a fixed quantity of effect across brands. The only honest comparison is the total price for the treatment of your area. We set out all six brands' labelled doses side by side on our unit conversion page.

For the glabella specifically, Jeuveau's labelled dose is 20 Units total: 0.1 mL, or 4 Units, into each of five sites. One injection into the procerus and two into each corrugator supercilii.

The one thing it is approved for

Jeuveau is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, the vertical "11s" between the brows, associated with corrugator and procerus muscle activity, in adults.

That is the entire approved indication. And unusually, the label's boxed warning spells out the limit rather than leaving it implied: "JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines."

So a forehead treatment, crow's feet, a masseter, a lip flip or anything medical is off-label with this product. Off-label use is legal and common, and a licensed injector may make that judgement. It does mean no regulator has reviewed a dose or an injection map for it. If you want a product with an approved forehead and crow's feet dose, that is Botox, and our glabellar lines page covers the area itself across products.

The boxed warning's main subject is distant spread of toxin effect: symptoms consistent with botulinum toxin appearing away from the injection site, reported hours to weeks afterwards, with swallowing and breathing difficulties that can be life threatening and reports of death. That warning is on every product in this class, not just this one. The realistic risk at 20 units in a glabella is very low, but the warning exists because the mechanism is real.

What it costs, and how to compare honestly

Evolus does not publish a patient price and we do not publish figures we cannot source. What is reliable is the structure of the pricing and what actually moves it.

Jeuveau is sold per unit, and its labelled glabellar dose is 20 units. So for the one area it is approved for, the comparison you want is 20 units of Jeuveau against the labelled dose of whatever else is on offer for the same area, at each clinic's own per-unit rate. Comparing per-unit prices alone tells you nothing, for the assay reason above.

From the verified prices we collect on our city pages, three things move injectable pricing more than the brand does: who injects, whether the quoted rate is a first-visit price, and whether a minimum spend applies. One Denver clinic publishes a 23 per cent premium for the physician over the nurse injector for the same product. In Chicago the lowest published rate we found rises 44 per cent on the second visit. Our Botox price guide goes through the same patterns in detail.

What to ask before you agree

Is my treatment area inside the approval? Only the glabella is. Everything else with this product is off-label.
How many units, in total, and at what rate? The labelled glabellar dose is 20. A per-unit price is not comparable across brands.
Why Jeuveau rather than another brand? A good answer will be about your face or your history, not about a promotion.
What is the plan if I get a droopy lid? That is the reaction the trials attribute to the drug, at 2%.
When can I be treated again? The label sets a floor of three months, and says the cumulative dose has to be considered.
Who is injecting, and can I verify their licence? You can, in every state, and it takes about two minutes. See how to verify an injector's licence.

If you are weighing Jeuveau against Botox specifically, our Botox vs Jeuveau comparison puts the two labels side by side. For the other brands, see Dysport, Xeomin, Daxxify and Letybo.

Frequently asked questions

What is Jeuveau approved for?

One thing: the temporary improvement in the appearance of moderate to severe glabellar lines, the vertical lines between the brows, in adults. The label is unusually explicit about the limit, because its boxed warning states that Jeuveau is not approved for the treatment of spasticity or any conditions other than glabellar lines. Forehead lines, crow's feet, masseter and every medical use are off-label with this product.

Does Jeuveau cause headaches?

Its own trial did not show that. The label reports headache in 12% of the 492 people who received Jeuveau and in 13% of the 162 who received placebo, so it was marginally more common among people given no drug at all. Headaches do happen after injections, and the placebo arm is the measure of how many would have happened anyway. The reaction the trials do attribute to the drug is eyelid ptosis, at 2% against 0% on placebo.

How long does Jeuveau last?

The label does not say. There is no statement of duration of effect in it, and the only efficacy timepoint the trials report is Day 30. What the label does state is that retreatment should be given no more frequently than every three months, which is a minimum safe interval rather than a claim about when the effect fades. So the widely quoted "three to four months" is extrapolated from practice and from the other toxins, not quoted from this approval.

How many units of Jeuveau do I need?

For the glabellar lines it is approved for, the labelled dose is 20 Units in total: 0.1 mL, which is 4 Units, into each of five sites, one in the procerus muscle and two in each corrugator supercilii. Any other area has no labelled dose for this product.

Is Jeuveau cheaper than Botox?

Sometimes per unit, but that comparison does not mean what it appears to. Jeuveau's potency is set by an assay specific to Evolus's own product, and the label states that its units cannot be converted into units of any other botulinum toxin. So a unit of one brand is not a unit of effect of another. The only honest comparison is the total price for treating your area.

Is Jeuveau as effective as Botox?

No trial has compared them directly, so no published evidence ranks them. What can be said is that Jeuveau cleared a strict bar in its own trials: 68% and 70% of patients achieved a 2-grade improvement on a 4-point scale at Day 30, scored independently by both the investigator and the patient, against a 1% placebo rate.

Who makes Jeuveau, and is it the same as Botox?

Evolus makes it, and no. Jeuveau is prabotulinumtoxinA-xvfs and Botox is onabotulinumtoxinA. Both are botulinum toxin type A and both work by blocking acetylcholine release, but they are different products with different potency assays, different approved indications and different labels. Jeuveau is often marketed as the cosmetic-only option, which matches its single approved indication.

Sources

Every figure on this page was read from the documents below rather than from a clinic or a manufacturer's marketing. They open in a new tab so you can check any claim here against its source.

JEUVEAU (prabotulinumtoxinA-xvfs) for injection, full prescribing information, US National Library of Medicine, DailyMed
Drugs@FDA approval database, US Food and Drug Administration
FDA-approved botulinum toxin products, US Food and Drug Administration

Written by

Lucas Pradella

Founder & Lead Researcher, BestBotoxClinics.com

Lucas founded BestBotoxClinics.com to bring clarity to the aesthetics industry, bringing 13+ years of experience in digital research and analysing online data for signals of quality and trust. He is not a physician, his work is research, data analysis and verifying provider credentials.

More about Lucas · How we work

Medical accuracy: BestBotoxClinics.com maintains a Medical Review Board of licensed clinicians. This article is educational and is not medical advice.